Romania Despite the challenging characteristics of the Romanian market, with a large population of nearly 20 million people and significant unmet medical needs, the country will undoubtedly continue to be strategic to multinationals in the region. This also means a consistent cycling of general managers, whether they are dispatched to the…

Medtech Key stakeholders within the Czech medtech industry highlight how medical devices can improve efficiency and quality of care across the country’s healthcare landscape, why greater levels of collaboration are of vital importance to achieving this, and how the Czech Republic stands out in the CEE region for its uptake of…

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Romania Quite unfortunately, Romania has some of the highest infant mortality and maternal mortality rates in Europe, and even more worrying, the downward trend seems to be continuing, most notably with significant measles outbreaks occurring in the country every year since 2016. Part of this distressing phenomenon relates to a growing…

Romania Appointed in August 2019 to head up Bayer Romania and Moldova’s Pharmaceuticals division, 15-year Bayer veteran Jorge Levinson may be new to the market but certainly not new to the general manager position.     Every country has its challenges and opportunities Jorge Levinson, Bayer   He laughs, “this is…

Czech Republic The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning that it stands out as one of Central and Eastern Europe’s top destinations for clinical trials. However, a decline in the number of clinical trials in recent years means that Czech stakeholders are looking to…

Czech Republic In 1996 Jiří Žák, chairman & current CEO of FARMAK, borrowed half a billion Czech crowns to take over a state-owned producer of vitamins for which he had started working almost 30 years previously.   My goal is to continue reinvesting our profits to keep growing and leave behind a…

Czech Republic As one of the few pharma companies in the Czech Republic to offer products across the whole healthcare spectrum, including prescription drugs, generics, over-the-counter (OTC) treatments, and food supplements, the 125-year-old German firm STADA has established a strong Czech affiliate in recent times.   The beauty of STADA is that…

Belgium Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to the latest EFPIA data. The country has a long-established tradition of excellence in clinical trials and AmCham Belgium estimates that…

UK With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as one of the world’s top life science investment destinations and multinational pharma firms including Novartis are already taking note.   “Tangible Opportunity” In February 2020, the…

Czech Republic Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before being able to enter the market.   While the timelines are still outside the defined framework, the situation is much…

Czech Republic A cross-industry push for better and broader access to innovative treatments is underway in the Czech Republic. Ripe for reform is the country’s orphan drug legislation as no standard pathway for their assessment, pricing and reimbursement currently exists.   [For cancer treatment the country has been] quite successful in moving…